$APP

Stumpf Matthew sold $5.4M of APP

Stumpf Matthew (Chief Financial Officer (CFO)) sold 9,052 shares of AppLovin Corp (APP) at $600.00 ($5.43M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Stumpf Matthew
Published May 29, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$APP
Neutral
medium confidence
Mentioned
$APP
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APPNeutralLow
01

Why it matters

The disclosed sale provides incremental information about insider liquidity and potential sentiment, but the 10b5-1 structure generally limits inference about near-term fundamentals.

02

Market read

A single officer sale is typically a low-signal event; any trading impact is likely short-lived unless corroborated by additional filings or fundamental news.

03

What to watch

Traders may overreact to single Form 4 prints; the key is whether there is a pattern of repeated sales outside normal schedules or alongside other negative disclosures.

Relevance 6/10Novelty 6/10Timing: Filed today (2026-05-29) following a 2026-05-28 sale disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for AppLovin’s CFO selling shares under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$APPNeutralMedium confidence
Context

AppLovin CFO Matthew Stumpf sold $5.43M of APP shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low/limited immediate impact; any move is likely sentiment-driven and fades unless follow-on selling accelerates.

Evidence & confidence

The filing is a routine officer sale with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is on a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • AppLovin Corp

    Subject of the insider transaction disclosure (SEC Form 4).

  • Matthew Stumpf

    CFO who executed the open-market sale of APP shares.

Related articles

$APPMed

Applovin stock hits 52-week low at 341.42 USD

AppLovin shares fell to near a 52-week low around $341 to $343, down about 38% year-to-date, according to Investing.com. The article cites Q2 2026 revenue of $1.92B vs $1.95B expected and current-quarter guidance midpoint of $2.07B vs $2.08B. Several analysts cut price targets or ratings after the misses.

$APPMedAI 8/10

AppLovin (APP) Stock Trades Down, Here Is Why

AppLovin (NASDAQ: APP) shares fell 18.6% after the company reported Q2 2026 results below expectations. Revenue was $1.92B versus $1.95B estimates, and Q3 guidance was $2.07B versus $2.08B consensus, according to the company and analysts. Wells Fargo and Piper Sandler downgraded the stock, citing the revenue miss and growth concerns.

$APPMed

Dow slips, Nasdaq moves level as earnings keep markets on edge

U.S. stocks opened mixed as investors digested earnings and economic data. AppLovin (APP) fell over 20% after Q2 revenue of $1.924B missed estimates. Datadog (DDOG) dropped over 18% on weaker bookings and guidance. SpaceX (SPCX) rose about 2.5% after a lockup expiry. Western Digital (WDC) slid 11% on margin outlook; Fiserv (FI) and Kenvue (KVUE) also fell.

$APPMedAI 8/10

Why AppLovin Stock Tumbled Today

AppLovin (NASDAQ: APP) shares fell about 19.6% in early trading after the company reported Q2 results that missed expectations. Revenue rose 53% to $1.92B versus $1.94B consensus. GAAP EPS increased to $3.76, slightly above $3.75. Q3 revenue guidance of $2.055B-$2.085B and adjusted EBITDA outlook also trailed consensus.